JP2009535036A - Ｃ型肝炎ウイルス感染症のバイオマーカー - Google Patents

Ｃ型肝炎ウイルス感染症のバイオマーカー Download PDF

Info

Publication number
JP2009535036A
JP2009535036A JP2009507945A JP2009507945A JP2009535036A JP 2009535036 A JP2009535036 A JP 2009535036A JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009535036 A JP2009535036 A JP 2009535036A
Authority
JP
Japan
Prior art keywords
subject
hcv
gene
expression
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535036A5 (enExample
Inventor
ラビ・ケイ・ラマチャンドラン
マシュー・ダブリュー・ハーディング
ポール・アール・キャロン
マーティン・シー・ボットフィールド
ブライアン・ジェイ・ヘアー
ラジ・バンダル
ケビン・エム・ケリハー
キャサリン・エヌ・コーネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009535036A publication Critical patent/JP2009535036A/ja
Publication of JP2009535036A5 publication Critical patent/JP2009535036A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009507945A 2006-04-26 2007-04-25 Ｃ型肝炎ウイルス感染症のバイオマーカー Pending JP2009535036A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
PCT/US2007/067421 WO2007127801A2 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Publications (2)

Publication Number Publication Date
JP2009535036A true JP2009535036A (ja) 2009-10-01
JP2009535036A5 JP2009535036A5 (enExample) 2010-06-17

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507945A Pending JP2009535036A (ja) 2006-04-26 2007-04-25 Ｃ型肝炎ウイルス感染症のバイオマーカー

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
CA2738477A1 (en) * 2008-09-24 2010-04-01 Robert S. Kauffman Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis
EP2561363B1 (en) 2010-04-21 2021-07-14 Memed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
EP3129036B1 (en) * 2014-04-11 2021-08-11 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA3190715A1 (en) 2014-08-14 2016-02-18 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016026258A1 (en) * 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
WO2016092554A1 (en) 2014-12-11 2016-06-16 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
EP3423589B1 (en) 2016-03-03 2021-07-21 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
CA3022616A1 (en) 2016-06-07 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CN109661578B (zh) 2016-07-10 2022-05-10 米密德诊断学有限公司 用于区分细菌和病毒感染的蛋白质特征
EP3519834A4 (en) 2016-09-29 2020-06-17 MeMed Diagnostics Ltd. RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS
EP3519833B1 (en) 2016-09-29 2024-08-14 MeMed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073599A2 (en) * 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
AU2005321808B2 (en) * 2004-12-30 2009-08-20 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012034399; Ｈｅｐａｔｏｌｏｇｙ Ｖｏｌ．４２, 2005, ｐ．７０２-７１０ *
JPN6012034401; Ｖｉｒｏｌｏｇｙ Ｖｏｌ．２９５, 2002, ｐ．２７２-２８３ *
JPN6012034403; Ａｎｔｉｍｉｃｒｏｂ．　Ａｇｅｎｔｓ　Ｃｈｅｍｏｔｈｅｒ． Ｖｏｌ．５０，　Ｎｏ．３, 200603, ｐ．８９９-９０９ *
JPN6012034406; Ｊ．　Ｈｅｐａｔｏｌｏｇｙ Ｖｏｌ．４４，　Ｎｏ．ｓｕｐ２, 200604, ｐ．Ｓ２２３ *

Also Published As

Publication number Publication date
WO2007127801A2 (en) 2007-11-08
AU2007244824A1 (en) 2007-11-08
EP2016195A4 (en) 2010-03-10
IL194920A0 (en) 2009-08-03
MX2008013796A (es) 2009-03-31
CA2650616A1 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04
CN101479389A (zh) 2009-07-08
NZ573052A (en) 2012-03-30
WO2007127801A3 (en) 2008-09-12
NO20084954L (no) 2009-01-22
KR20090023360A (ko) 2009-03-04
EP2016195A2 (en) 2009-01-21
RU2008146518A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
JP2009535036A (ja) Ｃ型肝炎ウイルス感染症のバイオマーカー
Meissner et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Taylor et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy
Naggie et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response
O’Brien et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance
AU2009240021B2 (en) Antiviral therapy
JP2007529714A (ja) 遺伝子分析のための方法
EP2191274A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
JP2010520744A (ja) Ｈｃｖに感染した患者の医薬品感受性を調べる方法およびキット
Kamal Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
Ito et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection
Covolo et al. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection
Suda et al. Serum granulysin levels as a predictor of serious telaprevir‐induced dermatological reactions
Naga et al. Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level
Selzner et al. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients
Ogawa et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure
Shaker et al. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients
Katsounas et al. CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon‐α therapy and toll‐like receptor 3 signalling
Kumada et al. Efficacy and safety of telaprevir with pegylated interferon α‐2a and ribavirin in Japanese patients
JP2017502663A (ja) Ｈｂｖ治療反応に関するバイオマーカー
Lim et al. The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese
HK1130843A (en) Hepatitis c virus infection biomarkers
Moudi et al. The relationship between L-leucine-7-amido-4-methyl coumarin 1 gene polymorphism and susceptibility to the chronic hepatitis B virus infection in an Iranian population
Masaki et al. Pretreatment prediction of the outcome of response‐guided peginterferon‐α and ribavirin therapy for chronic hepatitis C
Savasçi et al. Interleukin 28b Gene Polymorphysim in Patients With Chronic Hepatitis C

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130319